ScreenerHero

VTGN Vistagen Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · vistagen.com
0.2471USD-1.40%Mkt Cap: 10.97M $P/E: —

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline inclu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.97M USD
Enterprise Value-19.83M USD
Revenue (TTM)2.50M USD
Gross Profit2.50M USD
Net Income (TTM)-69.69M USD
Revenue/Share0.06 USD
Last Price0.2471 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.16
PEG—
EV/EBITDA0.28
EV/Revenue-7.93
P/S4.45
P/B0.45
EPS (TTM)-1.57
EPS (Forward)-1.54
52W Range
0.19801% of range5.140
52W High5.140 USD
52W Low0.1980 USD
Profitability
Gross Margin100.00%
Oper. Margin-904.34%
EBITDA Margin0.00%
Profit Margin-5491.33%
ROE-196.19%
ROA-143.49%
Growth
Revenue Growth504.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.44M USD
CapEx (TTM)151.00K USD
FCF Margin-1477.44%
FCF Yield-336.97%
Net Debt-30.95M USD
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity0.03
Current Ratio3.07
Quick Ratio2.83
Book Value/Sh0.55 USD
Cash/Share0.71 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 7, 2023
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.000 USD
Upside (mean)+304.7%
Target Range1.000 USD – 1.000 USD
# Analysts2
Ownership
Shares Out.44.38M
Float41.42M
Insiders0.37%
Institutions31.05%
Short Interest
Short Ratio4.7d
Short % Float6.12%
Short % Out.6.10%
Shares Short2.71M
Short (prev mo.)1.95M
Technical
SMA 500.2588 (-4.5%)
SMA 2000.4943 (-50.0%)
Beta0.33
S&P 52W Chg16.45%
Avg Vol (30d)21.00M
Avg Vol (10d)62.27M
Technical Indicators
RSI (14)44.3
MACD-0.0001
MACD Signal0.0022
MACD Hist.-0.0023
BB Upper0.3346 USD
BB Middle0.2668 USD
BB Lower0.1990 USD
BB Width50.82%
ATR (14)0.0352 USD
Vol Ratio (20d)0.02x